98%
921
2 minutes
20
It remains unclear to what extent neurodevelopmental disorder (NDD) risk genes retain functions into adulthood and how they may influence disease phenotypes. haploinsufficiency causes a severe NDD defined by autistic traits, cognitive impairment, and epilepsy. To determine if this gene retains therapeutically-relevant biological functions into adulthood, we performed a gene restoration technique in a mouse model for haploinsufficiency. Adult restoration of SynGAP protein improved behavioral and electrophysiological measures of memory and seizure. This included the elimination of interictal events that worsened during sleep. These events may be a biomarker for generalized cortical dysfunction in disorders because they also worsened during sleep in the human patient population. We conclude that SynGAP protein retains biological functions throughout adulthood and that non-developmental functions may contribute to disease phenotypes. Thus, treatments that target debilitating aspects of severe NDDs, such as medically-refractory seizures and cognitive impairment, may be effective in adult patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504227 | PMC |
http://dx.doi.org/10.7554/eLife.46752 | DOI Listing |
Mol Psychiatry
August 2025
Furong Laboratory, Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, 410078, Hunan, P. R. China.
The Ras GTPase-activating protein SynGAP interacts with PSD95 to regulate synaptic morphology and function at the postsynaptic density in neurons. Haploinsufficiency of SYNGAP1 has been linked to autism spectrum disorders (ASD) and intellectual disability (ID). While transcriptional and translational regulation of SYNGAP1 has been extensively explored, the mechanisms governing its protein homeostasis remain largely elusive.
View Article and Find Full Text PDFPediatr Neurol
August 2025
Weill Cornell Medicine, New York, New York; NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York. Electronic address:
Background: SYNGAP1 is a heterogeneous genetic disorder associated with intellectual disability, infantile-onset seizures, and other neurological and somatic symptoms. Clinical trial design for SYNGAP1 would benefit from a disease concept model-i.e.
View Article and Find Full Text PDFEpilepsia
May 2025
Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Objective: SYNGAP1-related disorders are common neurodevelopmental conditions characterized by autism spectrum disorder, developmental delay, intellectual disability, and a range of generalized seizure types. Disease-causing variants in SYNGAP1 typically occur de novo. This study aims to characterize inherited cases of SYNGAP1-related disorders.
View Article and Find Full Text PDFeNeuro
May 2025
Rosamund Stone Zander Translational Neuroscience Center, F. M. Kirby Center, Department of Neurology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts 02115
In the model of SYNGAP1-related intellectual disability (SRID), excessive neuronal protein synthesis is linked to deficits in synaptic plasticity. Here, we use Translating Ribosome Affinity Purification and RNA-seq (TRAP-seq) to identify mistranslating mRNAs in CA1 pyramidal neurons that exhibit occluded long-term potentiation (LTP). We find the translation environment is significantly altered in a manner that is distinct from the model of fragile X syndrome (FXS), another monogenic model of autism and intellectual disability.
View Article and Find Full Text PDF